All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
An antiretroviral drug regimen including Kaletra, which contains a small dose of Norvir to increase antiviral action, achieves the most rapid suppression of viral load in patients diagnosed with HIV infection when they already have severe immune system damage. A study in the November 1 edition of Journal of Acquired Immune Deficiency Syndromes showed that Kaletra reduced HIV in the blood by 70% during the first 24 hours of treatment in study subjects who began treatment with median CD4-cell counts of 32 and median viral loads of 500,000. By comparison, a regimen containing Crixivan reduced blood-based viral loads by 39%, while a Sustiva-based regimen cut viral loads by 29%. More than one third of the study subjects taking Kaletra had viral loads below 50 copies after 28 days of treatment; none of the patients on the other regimens achieved that viral load level. While all three regimens are effective in controlling HIV replication in the long term, patients with severe immune damage may best benefit from a Kaletra-based regimen to suppress viral loads as rapidly as possible.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Latest Stories
The Pride Store: Discover More LGBTQ+ & Ally Brands Tailor Made for Celebrating Your Identity
Shop Your Pride: Dive into LGBTQ+ & Ally Brands with The Grand Opening of The Pride Store
These Black Queer Podcasts (Featuring Literally Zero Cis White Gay Men) Deserve Your Ears
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
Trending stories
Most Recent
Recommended Stories for You
Bob Adams
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.